CY1107330T1 - Εκδοχα της πιπepαζινυλακυλπιπepιδινης, η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη - Google Patents
Εκδοχα της πιπepαζινυλακυλπιπepιδινης, η παρασκευη τους και η εφαρμογη τους στη θepαπευτικηInfo
- Publication number
- CY1107330T1 CY1107330T1 CY20061101094T CY061101094T CY1107330T1 CY 1107330 T1 CY1107330 T1 CY 1107330T1 CY 20061101094 T CY20061101094 T CY 20061101094T CY 061101094 T CY061101094 T CY 061101094T CY 1107330 T1 CY1107330 T1 CY 1107330T1
- Authority
- CY
- Cyprus
- Prior art keywords
- group
- denotes
- therapeutic
- application
- pipepazynylacylpepepdinin
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- -1 1,3-thiazol-2-yl Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Η εφεύρεση αφορά τα έκδοχα υποκατάστατων 1 πιπεραζινυλακυλπιπεριδίνης, γενικού τύπου (I), όπου: n είναι 1 ή 2, To R1 δηλώνει ένα άτομο αλογόνου, μια ομάδα τριφθοριομεθυλίου, ένα (C1-C4) αλκύλιο, ένα (C1-C4) άλκοξυ, μια ομάδα τριφθοριομέθοξυ. To R2 δηλώνει ένα άτομο υδρογόνου, ή ένα άτομο αλογόνου, το R3 δηλώνει ένα άτομο υδρογόνου, μια ομάδα -OR5, μια ομάδα -CH2OR5, μια ομάδα -NR6 R7, μια ομάδα -NR8COR9, μια ομάδα -NR8CONR10R11, μια ομάδα -CH2NR12R13, μια ομάδα -CH2NR8CONR14R15, ένα (C1-C4)αλκοξυκαρβονύλιο, μια ομάδα -CONR16R17, ή το R3 αποτελεί έναν διπλό σύνδεσμο μεταξύ του ατόμου του άνθρακα με το οποίο συνδέεται και του διπλανού ατόμου του άνθρακα του κύκλου πιπεριδίνης, το R4 δηλώνει την αρωματική ομάδα 1,3-θιαζόλ-2-υλιο του τύπου (II). Διαδικασία παρασκευής και εφαρμογή στη θεραπευτική.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0207001 | 2002-06-07 | ||
| EP03757109A EP1513836B1 (fr) | 2002-06-07 | 2003-06-05 | Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107330T1 true CY1107330T1 (el) | 2012-11-21 |
Family
ID=29724874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101094T CY1107330T1 (el) | 2002-06-07 | 2006-08-03 | Εκδοχα της πιπepαζινυλακυλπιπepιδινης, η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη |
| CY20061101660T CY1105784T1 (el) | 2002-06-07 | 2006-11-15 | Εκδοχα της πιπepαζινυλακυλπιπepιδινης η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101660T CY1105784T1 (el) | 2002-06-07 | 2006-11-15 | Εκδοχα της πιπepαζινυλακυλπιπepιδινης η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7294628B2 (el) |
| EP (2) | EP1513836B1 (el) |
| JP (2) | JP4441401B2 (el) |
| KR (1) | KR100970812B1 (el) |
| CN (1) | CN100448875C (el) |
| AR (2) | AR040247A1 (el) |
| AT (2) | ATE325122T1 (el) |
| AU (2) | AU2003255644B2 (el) |
| BR (1) | BR0311828A (el) |
| CA (1) | CA2487840C (el) |
| CY (2) | CY1107330T1 (el) |
| DE (2) | DE60307632T2 (el) |
| DK (2) | DK1513835T3 (el) |
| EA (1) | EA007501B1 (el) |
| ES (2) | ES2271637T3 (el) |
| HK (1) | HK1076110A1 (el) |
| HR (1) | HRP20041157B1 (el) |
| IS (1) | IS2302B (el) |
| MA (1) | MA27233A1 (el) |
| ME (1) | MEP11508A (el) |
| MX (1) | MXPA04012341A (el) |
| NO (1) | NO329669B1 (el) |
| NZ (1) | NZ537044A (el) |
| PL (1) | PL208711B1 (el) |
| PT (2) | PT1513836E (el) |
| RS (2) | RS20050014A (el) |
| TW (2) | TWI283671B (el) |
| UA (1) | UA77526C2 (el) |
| WO (2) | WO2003104226A1 (el) |
| ZA (1) | ZA200409823B (el) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2862968B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
| FR2862967B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
| US7723362B2 (en) * | 2004-01-08 | 2010-05-25 | Syngenta Crop Protection, Inc. | Pesticidal heterocyclic dihaloallyl compounds |
| WO2006008259A1 (en) * | 2004-07-16 | 2006-01-26 | Janssen Pharmaceutica N.V. | Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders |
| WO2006034315A2 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| EP2594318B1 (en) * | 2005-04-15 | 2020-06-10 | University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
| WO2008115381A1 (en) * | 2007-03-15 | 2008-09-25 | Schering Corporation | Pyridazinone derivatives useful as glucan synthase inhibitors |
| BRPI0811844A2 (pt) * | 2007-05-21 | 2014-11-18 | Reviva Pharmaceuticals Inc | Composto, e, método para tratar um paciente |
| DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| FR2932482B1 (fr) * | 2008-06-13 | 2010-10-08 | Sanofi Aventis | Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
| FR2932481B1 (fr) | 2008-06-13 | 2010-10-08 | Sanofi Aventis | Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique. |
| CN104761515B (zh) | 2009-11-12 | 2018-03-09 | 特罗菲克斯制药股份有限公司 | 神经营养蛋白模拟化合物及其盐的晶型 |
| US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| FR2953839A1 (fr) | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
| CN102666489B (zh) | 2009-12-14 | 2014-07-23 | 默克专利有限公司 | 鞘氨醇激酶抑制剂 |
| FR2953836B1 (fr) * | 2009-12-14 | 2012-03-16 | Sanofi Aventis | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
| EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
| US20230203028A1 (en) * | 2017-09-18 | 2023-06-29 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| IL281438B2 (en) | 2018-09-18 | 2023-12-01 | Goldfinch Bio Inc | Pyridazinones and methods of using them |
| EP3858439A1 (en) * | 2020-02-03 | 2021-08-04 | Esteve Pharmaceuticals, S.A. | Amide derivatives having multimodal activity against pain |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU208690B (en) * | 1987-10-26 | 1993-12-28 | Pfizer | Process for producing 1-hjeterocyclic sulfonyl-3-(pyrimidinyl piperazinyl)-propane derivatives and pharmaceutical compositions comprising same |
| FR2747041B1 (fr) * | 1996-04-05 | 1998-05-22 | Cird Galderma | Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies |
| US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| FR2803593B1 (fr) * | 2000-01-06 | 2002-02-15 | Sanofi Synthelabo | Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant |
-
2003
- 2003-05-06 UA UA20041210010A patent/UA77526C2/uk unknown
- 2003-06-05 RS YUP-2005/0014A patent/RS20050014A/sr unknown
- 2003-06-05 ES ES03757108T patent/ES2271637T3/es not_active Expired - Lifetime
- 2003-06-05 DE DE60307632T patent/DE60307632T2/de not_active Expired - Lifetime
- 2003-06-05 BR BR0311828-2A patent/BR0311828A/pt not_active IP Right Cessation
- 2003-06-05 US US10/516,808 patent/US7294628B2/en active Active
- 2003-06-05 AU AU2003255644A patent/AU2003255644B2/en not_active Ceased
- 2003-06-05 MX MXPA04012341A patent/MXPA04012341A/es active IP Right Grant
- 2003-06-05 CA CA2487840A patent/CA2487840C/en not_active Expired - Fee Related
- 2003-06-05 AU AU2003255645A patent/AU2003255645A1/en not_active Abandoned
- 2003-06-05 JP JP2004511296A patent/JP4441401B2/ja not_active Expired - Fee Related
- 2003-06-05 PT PT03757109T patent/PT1513836E/pt unknown
- 2003-06-05 PT PT03757108T patent/PT1513835E/pt unknown
- 2003-06-05 RS RS20050014A patent/RS52588B/en unknown
- 2003-06-05 CN CNB038188082A patent/CN100448875C/zh not_active Expired - Fee Related
- 2003-06-05 NZ NZ537044A patent/NZ537044A/en not_active IP Right Cessation
- 2003-06-05 EP EP03757109A patent/EP1513836B1/fr not_active Expired - Lifetime
- 2003-06-05 PL PL374729A patent/PL208711B1/pl not_active IP Right Cessation
- 2003-06-05 EA EA200401470A patent/EA007501B1/ru not_active IP Right Cessation
- 2003-06-05 AT AT03757109T patent/ATE325122T1/de active
- 2003-06-05 ES ES03757109T patent/ES2264001T3/es not_active Expired - Lifetime
- 2003-06-05 AT AT03757108T patent/ATE336491T1/de active
- 2003-06-05 DK DK03757108T patent/DK1513835T3/da active
- 2003-06-05 WO PCT/FR2003/001686 patent/WO2003104226A1/fr active IP Right Grant
- 2003-06-05 JP JP2004511295A patent/JP4437075B2/ja not_active Expired - Fee Related
- 2003-06-05 WO PCT/FR2003/001685 patent/WO2003104225A1/fr active IP Right Grant
- 2003-06-05 ME MEP-115/08A patent/MEP11508A/xx unknown
- 2003-06-05 EP EP03757108A patent/EP1513835B1/fr not_active Expired - Lifetime
- 2003-06-05 KR KR1020047019860A patent/KR100970812B1/ko not_active IP Right Cessation
- 2003-06-05 US US10/516,704 patent/US7468368B2/en active Active
- 2003-06-05 DK DK03757109T patent/DK1513836T3/da active
- 2003-06-05 DE DE60305037T patent/DE60305037T2/de not_active Expired - Lifetime
- 2003-06-06 AR ARP030102018A patent/AR040247A1/es active IP Right Grant
- 2003-06-06 TW TW092115416A patent/TWI283671B/zh not_active IP Right Cessation
- 2003-06-06 TW TW092115443A patent/TWI319400B/zh not_active IP Right Cessation
- 2003-06-06 AR ARP030102017A patent/AR040246A1/es active IP Right Grant
-
2004
- 2004-12-02 IS IS7579A patent/IS2302B/is unknown
- 2004-12-03 MA MA27980A patent/MA27233A1/fr unknown
- 2004-12-03 ZA ZA200409823A patent/ZA200409823B/en unknown
- 2004-12-06 HR HR20041157 patent/HRP20041157B1/xx not_active IP Right Cessation
- 2004-12-06 NO NO20045331A patent/NO329669B1/no not_active IP Right Cessation
-
2005
- 2005-11-19 HK HK05110460.5A patent/HK1076110A1/xx not_active IP Right Cessation
-
2006
- 2006-08-03 CY CY20061101094T patent/CY1107330T1/el unknown
- 2006-11-15 CY CY20061101660T patent/CY1105784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107330T1 (el) | Εκδοχα της πιπepαζινυλακυλπιπepιδινης, η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη | |
| CY1122863T1 (el) | Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα | |
| CY1107008T1 (el) | Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii | |
| CY1112005T1 (el) | Νεα καρβοξαμιδια ως αναστολεις του παραγοντα χa | |
| NO20061126L (no) | Aminopyroner og deres anvendelse som ATM-inhibitorer | |
| CY1114452T1 (el) | Ενωσεις πυρρολιου | |
| CY1115533T1 (el) | Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr | |
| NO20062020L (no) | 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika | |
| CY1105344T1 (el) | Αμινουχα παραγωγα της διυδρο- 1,3,5 - τριαζινης και οι εφαρμογες τους στη θepαπευτικη | |
| CY1106509T1 (el) | Αμιδοακετονιτριλια κατα των παρασιτων του εντερου | |
| CY1108025T1 (el) | Παραγωγα n-[φαινυλο (πιπεριδινο-2-υλο)μεθυλο] βενζαμιδιου, η διαδικασια παρασκευης τους και η εφαρμογη τους στη θεραπευτικη | |
| CY1108744T1 (el) | 2-οξο-1,2,4,5-τετραϋδρo-1,3-βενζοδιαζεπιν-3-υλ-πιπεριδινες ως ανταγωνιστες της cgrp | |
| BRPI0506927A (pt) | compostos orgánicos | |
| CY1105330T1 (el) | Καρβαμιδικα παραγωγα για χρηση στην προληψη ή την αγωγη της διπολικης διαταραχης | |
| CY1111349T1 (el) | Καρβαμιδικες ενωσεις προς χρηση στη θεραπεια του πονου | |
| ATE478044T1 (de) | Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c | |
| UY27055A1 (es) | Activadores heteroaromaticos fusionados de la glucoquinasa | |
| CY1105337T1 (el) | Πρωτοτυπες διυδροπτepιδινονες, μεθοδος για την παραγωγη τους και η χρηση τους ως φαρμακευτικα μεσα | |
| NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
| CY1110284T1 (el) | Παραγωγα της 2-αμινο-4-πυριδυλομεθυλο-θειαζολινης και η χρηση τους ως αναστολεις της επαγωγιμης συνθασης νο | |
| CY1107468T1 (el) | Καρβαμιδικες ενωσεις για χρηση στην προληψη ή την αγωγη διαταραχων του αγχους | |
| CY1106356T1 (el) | Νεα υποκατεστημενα παραγωγα 4-φαινυλ-4-[1η-ιμιδαζολ-2-υλ]-πιπepιδινης και η χρηση τους ως επιλεκτικοι μη-πεπτιδικοι δελτα οπιοειδεις συναγωνιστες | |
| EA200700758A1 (ru) | Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ | |
| TW200607808A (en) | Pyrido-pyrimidine derivatives, preparation thereof and application thereof | |
| CO5700773A2 (es) | Derivados de bencimidazol |